	US 12,234,516 B2
	Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof
Min Soo Kim, Grand Prairie, TX (US); James Brugarolas, Irving, TX (US); Tae Hyun Hwang, Dallas, TX (US); and Yang Xie, Coppell, TX (US)
Assigned to The Board of Regents of The University of Texas System, Austin, TX (US)
Filed by The Board of Regents of the University of Texas System, Austin, TX (US)
Filed on Mar. 19, 2021, as Appl. No. 17/206,895.
Application 17/206,895 is a division of application No. 15/761,534, abandoned, previously published as PCT/US2016/052118, filed on Sep. 16, 2016.
Claims priority of provisional application 62/221,527, filed on Sep. 21, 2015.
Prior Publication US 2021/0222257 A1, Jul. 22, 2021
Int. Cl. C12Q 1/6886 (2018.01); A61P 35/00 (2006.01); C12N 15/52 (2006.01); C40B 40/08 (2006.01); G01N 33/50 (2006.01); G16B 25/00 (2019.01); G16B 25/10 (2019.01); G16B 25/20 (2019.01); G16B 30/00 (2019.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01)

CPC C12Q 1/6886 (2013.01) [A61P 35/00 (2018.01); C12N 15/52 (2013.01); C40B 40/08 (2013.01); G01N 33/5091 (2013.01); G16B 25/00 (2019.02); G16B 25/10 (2019.02); G16B 25/20 (2019.02); G16B 30/00 (2019.02); G16H 50/20 (2018.01); G16H 50/30 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/7028 (2013.01)]

5 Claims

1. A method of treating a plurality of human renal cell carcinoma cells with a HIF-2α inhibitor, comprising:

(a) assessing, by nucleic acid hybridization assay and/or protein assay, an expression level of EPAS1 in a biological sample comprising a cancer cell of the plurality of cells, or a portion thereof; and

(b) administering an effective dose of the HIF-2α inhibitor to the plurality of cells if EPAS1 is present in the sample at an increased expression level as compared to a cancer cell that is resistant to an HIF-2α inhibitor.